Instrument Inactif

Communiqués Sangui Biotech International, Inc. Hanseatische Wertpapierboerse Hamburg

Actions

SBH

US80105B1017

Recherche biotechnologique et médicale

Communiqués

10/02/21	Sangui BioTech International Inc.: Significant increase in sales in the first half year; Reduction of operating loss	EQ
09/02/21	SANGUI BIOTECH INTERNATIONAL : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
16/11/20	Sangui BioTech International Inc.: Significant increase in sales in the first quarter; Reduction of operating loss	EQ
13/11/20	SANGUI BIOTECH INTERNATIONAL : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
01/10/20	Sangui BioTech International Inc.: Sales of USD 28,915 in fiscal year 2020	EQ
30/09/20	SANGUI BIOTECH INTERNATIONAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
26/05/20	Sangui BioTech International Inc.: United States Patent Office grants patent 'Compositions for improved tissue oxygenation by peritoneal ventilation'	EQ
15/05/20	Sangui BioTech International Inc.: -Significant cost reductions in the first three quarters - Significant reduction of operating loss -Impairments caused by COVID - 19	EQ
14/05/20	SANGUI BIOTECH INTERNATIONAL : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
14/02/20	Sangui BioTech International Inc.: Significant cost reductions in the first half - year; Significant reduction of operating loss	EQ
13/02/20	SANGUI BIOTECH INTERNATIONAL : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
15/11/19	Sangui BioTech International Inc.: - Significant cost reductions in the first quarter; - Mölnlycke invests in warehouse capacities	EQ
09/10/19	Sangui BioTech International Inc.: Sales of USD 88,001 in fiscal year 2019	EQ
14/05/19	Sangui BioTech International Inc.: Sales of USD 63,429 in the first nine month	EQ
06/03/19	Sangui BioTech International Inc.: Patent granted to Sangui for possible Septic Shock treatment	EQ
14/02/19	Sangui BioTech International Inc.: - Sales of USD 55,367 in the first half-year; Strong year-end-business	EQ
15/11/18	Sangui BioTech International Inc.: - Sales of USD 11,272 in the first quarter - Mölnlycke takes over distribution of Granulox	EQ
02/10/18	Sangui BioTech International Inc.: Sales of USD 77,152 in fiscal year 2018; Costs and loss is further reduced	EQ
25/07/18	Sangui BioTech International Inc.: Revenues of USD 74,000 in fiscal year 2018; Introduction on the market of Granulox in Southeast Asia is proceeding according to plan; Foundation of Sangui Know-How - und Patentverwertungsgesellschaft mbH & Co. KG	EQ
03/07/18	Sangui BioTech International Inc.: World leader in wound care acquires SastoMed GmbH	EQ
22/05/18	Sangui BioTech International Inc.: - Granulox with the Annual Advanced Wound Care Award honored	EQ
04/05/18	Sangui BioTech International Inc.: - Sales of USD 65,273 in the first nine months, Costs and loss is further reduced	EQ
14/02/18	Sangui BioTech International Inc.: - Sales of USD 55,082 in the first half-year; - Costs and loss is further reduced	EQ
19/01/18	Sangui BioTech International Inc.: - Revenues of USD 54,000 in the first half-year; Granulox license income increased by 54%.	EQ
21/11/17	Sangui BioTech International Inc.: Sales of USD 16,636 in the first quarter; Costs and loss is further reduced	EQ